The Phase I-II study is a multicenter, open-label study of the X-linked inhibitor of apoptosis antisense AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)and follicular lymphoma (FL). It is being conducted at the Princess Margaret Hospital located in Toronto, Ontario.
The primary objective of this study is to determine the recommended dose of AEG35156 in patients with relapsed or refractory CLL, SLL and FL, and to determine the safety profile and response rate to AEG35156 in these patient populations.
Michael Berendt, president and CEO of Aegera, said: “Our clinical program around AEG35156 continues to expand and broaden as we seek to move this therapeutic forward to approval.
“By adding these lymphoma indications to AEG35156’s ongoing Phase I and II studies in leukemia, pancreatic, breast, and non-small cell lung cancer, we continue to seek to position AEG35156 as an important therapeutic option that could address important unmet medical needs across a spectrum of cancer indications.”